ANI Pharmaceuticals (NASDAQ:ANIP) Lowered to Sell at Zacks Investment Research
According to Zacks, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. “
A number of other brokerages have also commented on ANIP. Raymond James lowered ANI Pharmaceuticals from a strong-buy rating to an outperform rating and lifted their price objective for the stock from $73.00 to $82.00 in a research report on Friday, May 10th. Cantor Fitzgerald reiterated a buy rating and issued a $89.00 price objective on shares of ANI Pharmaceuticals in a research report on Thursday, May 9th. ValuEngine lowered ANI Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, August 1st. Canaccord Genuity restated a buy rating and set a $90.00 target price (up from $80.00) on shares of ANI Pharmaceuticals in a research report on Monday, May 13th. Finally, BidaskClub lowered ANI Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of Hold and a consensus target price of $89.00.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 EPS for the quarter, topping the Zacks’ consensus estimate of $1.18 by $0.26. The firm had revenue of $54.36 million during the quarter, compared to analyst estimates of $55.20 million. ANI Pharmaceuticals had a return on equity of 29.53% and a net margin of 8.14%. The company’s revenue was up 15.0% on a year-over-year basis. During the same period last year, the company earned $1.13 earnings per share. Sell-side analysts predict that ANI Pharmaceuticals will post 5.29 earnings per share for the current fiscal year.
In related news, Director David Nash bought 1,445 shares of the firm’s stock in a transaction dated Friday, May 24th. The stock was bought at an average cost of $68.76 per share, for a total transaction of $99,358.20. Following the transaction, the director now owns 5,236 shares of the company’s stock, valued at $360,027.36. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Meridian Venture Partners Ii L sold 19,860 shares of the business’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $71.70, for a total value of $1,423,962.00. The disclosure for this sale can be found here. Insiders have sold a total of 90,872 shares of company stock valued at $6,489,837 over the last 90 days. Corporate insiders own 24.70% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter worth about $32,000. Financial Gravity Wealth Inc. acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter worth about $54,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of ANI Pharmaceuticals by 237.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 794 shares of the specialty pharmaceutical company’s stock valued at $65,000 after purchasing an additional 559 shares in the last quarter. Quantamental Technologies LLC lifted its holdings in shares of ANI Pharmaceuticals by 169.4% during the 1st quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock valued at $61,000 after purchasing an additional 542 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its holdings in shares of ANI Pharmaceuticals by 55,466.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 1,667 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 1,664 shares in the last quarter. Institutional investors own 64.22% of the company’s stock.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Featured Story: Why is total return important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.